ScreenerHero

QTTBQ32 Bio Inc. Common Stock

NAS · US · Healthcare · Biotechnology · q32bio.com
15.97USD+0.82%Mkt Cap: 475.42M $P/E: 5.09

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap475.42M $
Enterprise Value371.17M $
Revenue (TTM)53.74M $
Gross Profit39.39M $
Net Income (TTM)29.82M $
Revenue/Share3.622 USD
Last Price15.97 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)5.09
P/E (Forward)-15.55
PEG—
EV/EBITDA17.01
EV/Revenue6.91
P/S8.79
P/B3.55
EPS (TTM)3.14
EPS (Forward)-1.02
52W Range
1.62065% of range23.57
52W High23.57 USD
52W Low1.620 USD
Profitability
Gross Margin73.30%
Oper. Margin39.94%
EBITDA Margin40.60%
Profit Margin55.49%
ROE70.98%
ROA48.27%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.54M $
CapEx (TTM)—
FCF Margin36.09%
FCF Yield4.08%
Net Debt-100.97M $
Net Debt/EBITDA-4.63
Balance Sheet
Debt/Equity0.37
Current Ratio20.30
Quick Ratio19.78
Book Value/Sh4.462 USD
Cash/Share3.570 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:18
Split DateMar 26, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)42.75 USD
Upside (mean)+167.7%
Target Range36.00 USD – 59.00 USD
$36.00+167.7% to mean$59.00
# Analysts4
Ownership
Shares Out.29.77M
Float14.47M
Insiders2.82%
Institutions76.14%
Short Interest
Short Ratio1.3d
Short % Float14.32%
Short % Out.10.08%
Shares Short3.00M
Short (prev mo.)677.05K
Technical
SMA 5014.49 (+10.2%)
SMA 2007.348 (+117.3%)
Beta-0.33
S&P 52W Chg18.16%
Avg Vol (30d)1.81M
Avg Vol (10d)361.00K
Technical Indicators
RSI (14)55.5
MACD0.4028
MACD Signal0.5048
MACD Hist.-0.1020
BB Upper16.46 USD
BB Middle15.58 USD
BB Lower14.71 USD
BB Width11.26%
ATR (14)1.166 USD
Vol Ratio (20d)0.76x